The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
作者： Caroline J. Voskens , Simone M. Goldinger , Carmen Loquai , Caroline Robert , Katharina C. Kaehler
DOI: 10.1371/JOURNAL.PONE.0053745
关键词: Retrospective cohort study 、 Medicine 、 Ipilimumab 、 Melanoma 、 Blocking antibody 、 Oncology 、 Internal medicine 、 Aseptic meningitis 、 Skin cancer 、 Immunology 、 Adverse effect 、 Eosinophilia
摘要: … effects is crucial. Therefore, we summarized rare and difficult-to-treat ipilimumab-induced side effects … In addition, we address specific hurdles, which we feel are critical for the success of …
core.ac.uk
harvard.edu
uzh.ch
doaj.org参考文章(49)
J. S. Weber, J. D. Wolchok, J. M. Richards, P. Lorigan, D. F. McDermott, W. J. Urba, V. DePril, K. N. Heller, R. A. Ibrahim, A. Hauschild, S. O'Day, Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. Journal of Clinical Oncology. ,vol. 29, pp. 8554- 8554 ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.8554
Shigeto Tohma, Miyuki Azuma, Manae Kurokawa, Shinji Oki, Kusuki Nishioka, Kazuhiko Yamamoto, Tetsufumi Inoue, Tomohiro Kato, Tetsuji Kobata, Toshihiro Matsui, Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. Journal of Immunology. ,vol. 162, pp. 4328- 4335 ,(1999)
Hua-Bing Wang, Fu-Dong Shi, Hulun Li, Benedict J. Chambers, Hans Link, Hans-Gustaf Ljunggren, Anti-CTLA-4 Antibody Treatment Triggers Determinant Spreading and Enhances Murine Myasthenia Gravis Journal of Immunology. ,vol. 166, pp. 6430- 6436 ,(2001) , 10.4049/JIMMUNOL.166.10.6430
Bart Neyns, Amélie Clémentine Seghers, Frederik Vandenbroucke, Stephanie Du Four, Sofie Wilgenhof, Hendrik Everaert, Veerle Morlion, Esther Vanderlinden, Shane Hanon, Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Research. ,vol. 32, pp. 1355- 1359 ,(2012)
J. M. Kirkwood, P. Lorigan, P. Hersey, A. Hauschild, C. Robert, D. McDermott, M. A. Marshall, J. Gomez-Navarro, J. Q. Liang, C. A. Bulanhagui, Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma Clinical Cancer Research. ,vol. 16, pp. 1042- 1048 ,(2010) , 10.1158/1078-0432.CCR-09-2033
Kaan Harmankaya, Christa Erasim, Claus Koelblinger, Ramy Ibrahim, Axel Hoos, Hubert Pehamberger, Michael Binder, Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy Medical Oncology. ,vol. 28, pp. 1140- 1144 ,(2011) , 10.1007/S12032-010-9606-0
Geoffrey Y. Ku, Jianda Yuan, David B. Page, Sebastian E. A. Schroeder, Katherine S. Panageas, Richard D. Carvajal, Paul B. Chapman, Gary K. Schwartz, James P. Allison, Jedd D. Wolchok, Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival Cancer. ,vol. 116, pp. 1767- 1775 ,(2010) , 10.1002/CNCR.24951
Fouad Fadel, Khalil El Karoui, Bertrand Knebelmann, Anti-CTLA4 antibody-induced lupus nephritis. The New England Journal of Medicine. ,vol. 361, pp. 211- 212 ,(2009) , 10.1056/NEJMC0904283
Flavie Bompaire, Christine Mateus, Hervé Taillia, Thierry De Greslan, Marion Lahutte, Magali Sallansonnet-Froment, Madani Ouologuem, Jean-Luc Renard, Guy Gorochov, Caroline Robert, Damien Ricard, Severe meningo-radiculo-nevritis associated with ipilimumab Investigational New Drugs. ,vol. 30, pp. 2407- 2410 ,(2012) , 10.1007/S10637-011-9787-1
Julie Delyon, Christine Mateus, Thierry Lambert, Hemophilia A Induced by Ipilimumab New England Journal of Medicine. ,vol. 365, pp. 1747- 1748 ,(2011) , 10.1056/NEJMC1110923